A RANDOMIZED COMPARISON OF A SIROLIMUS-ELUTING STENT WITH A STANDARD STENT FOR CORONARY REVASCULARIZATION

A BSTRACT Background The need for repeated treatment of restenosis of a treated vessel remains the main limitation of percutaneous coronary revascularization. Because sirolimus (rapamycin) inhibits the proliferation of lymphocytes and smooth-muscle cells, we compared a sirolimus-eluting stent with a standard uncoated stent in patients with angina pectoris. Methods We performed a randomized, double-blind trial to compare the two types of stents for revascularization of single, primary lesions in native coronary arteries. The trial included 238 patients at 19 medical centers. The primary end point was in-stent late luminal loss (the difference between the minimal luminal diameter immediately after the procedure and the diameter at six months). Secondary end points included the percentage of in-stent stenosis of the luminal diameter and the rate of restenosis (luminal narrowing of 50 percent or more). We also analyzed a composite clinical end point consisting of death, myocardial infarction, and percutaneous or surgical revascularization at 1, 6, and 12 months. Results At six months, the degree of neointimal proliferation, manifested as the mean (±SD) late luminal loss, was significantly lower in the sirolimusstent group (¡0.01±0.33 mm) than in the standardstent group (0.80±0.53 mm, P<0.001). None of the patients in the sirolimus-stent group, as compared with 26.6 percent of those in the standard-stent group, had restenosis of 50 percent or more of the luminal diameter (P<0.001). There were no episodes of stent thrombosis. During a follow-up period of up to one year, the overall rate of major cardiac events was 5.8 percent in the sirolimus-stent group and 28.8 percent in the standard-stent group (P<0.001). The difference was due entirely to a higher rate of revascularization of the target vessel in the standard-stent group. Conclusions As compared with a standard coronary stent, a sirolimus-eluting stent shows considerable promise for the prevention of neointimal proliferation, restenosis, and associated clinical events. (N Engl J Med 2002;346:1773-80.)

[1]  R. Califf,et al.  A Comparison of Directional Atherectomy with Coronary Angioplasty in Patients with Coronary Artery Disease , 1993 .

[2]  P. Tsao,et al.  Stent-Based Delivery of Sirolimus Reduces Neointimal Formation in a Porcine Coronary Model , 2001, Circulation.

[3]  S Marx,et al.  Inhibition of intimal thickening after balloon angioplasty in porcine coronary arteries by targeting regulators of the cell cycle. , 1999, Circulation.

[4]  Antonio Colombo,et al.  Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II) , 1998, The Lancet.

[5]  Lack of Neointimal Proliferation After Implantation of Sirolimus-Coated Stents in Human Coronary Arteries: A Quantitative Coronary Angiography and Three-Dimensional Intravascular Ultrasound Study , 2001 .

[6]  F Joffre,et al.  Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. , 1987, The New England journal of medicine.

[7]  P. Teirstein,et al.  A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. , 1994, The New England journal of medicine.

[8]  D. Baim,et al.  Novel approach to the analysis of restenosis after the use of three new coronary devices. , 1992, Journal of the American College of Cardiology.

[9]  W Rutsch,et al.  A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. , 1994, The New England journal of medicine.

[10]  E. Braunwald,et al.  Unstable angina. A classification. , 1989, Circulation.

[11]  Samin K. Sharma,et al.  Final results of the Balloon vs Optimal Atherectomy Trial (BOAT) , 1998, Circulation.

[12]  L Chiariello,et al.  A comparison of coronary-artery stenting with angioplasty for isolated stenosis of the proximal left anterior descending coronary artery. , 1997, The New England journal of medicine.

[13]  S. Marx,et al.  Bench to bedside: the development of rapamycin and its application to stent restenosis. , 2001, Circulation.

[14]  P. Serruys,et al.  A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. , 2002, The New England journal of medicine.

[15]  Larry S. Dean,et al.  Intracoronary Stenting for Acute and Threatened Closure Complicating Percutaneous Transluminal Coronary Angioplasty , 1992, Circulation.

[16]  Vos,et al.  Anti-restenosis Trials. , 2000, Current interventional cardiology reports.

[17]  C. Di Mario,et al.  Randomized Comparison of Coronary Stent Implantation Under Ultrasound or Angiographic Guidance to Reduce Stent Restenosis (OPTICUS Study) , 2001, Circulation.

[18]  R A Schatz,et al.  Catheter-based radiotherapy to inhibit restenosis after coronary stenting. , 1997, The New England journal of medicine.

[19]  M. Metcalfe,et al.  Rapamycin in transplantation: a review of the evidence. , 2001, Kidney international.

[20]  G. Stone,et al.  Treatment of in-stent restenosis with excimer laser coronary angioplasty versus rotational atherectomy: comparative mechanisms and results. , 2000, Circulation.

[21]  M. Leon,et al.  Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. , 1996, Circulation.

[22]  P. Serruys,et al.  Randomized Comparison of Primary Stenting and Provisional Balloon Angioplasty Guided by Flow Velocity Measurement , 2000, Circulation.

[23]  R E Vlietstra,et al.  Restenosis after percutaneous transluminal coronary angioplasty (PTCA): a report from the PTCA Registry of the National Heart, Lung, and Blood Institute. , 1984, The American journal of cardiology.

[24]  A. Kastrati,et al.  Increased risk of restenosis after placement of gold-coated stents: results of a randomized trial comparing gold-coated with uncoated steel stents in patients with coronary artery disease. , 2000, Circulation.

[25]  C. Wegner,et al.  Neointimal formation after balloon-induced vascular injury in Yucatan minipigs is reduced by oral rapamycin. , 1999, Journal of cardiovascular pharmacology.

[26]  M. Leon,et al.  Small stent size and intimal hyperplasia contribute to restenosis: a volumetric intravascular ultrasound analysis. , 1995, Journal of the American College of Cardiology.